Sun Pharmaceutical Industries Ltd. — M&A Activity 2018

Sep 10, 2018

==> picture [74 x 84] intentionally omitted <==

==> picture [230 x 120] intentionally omitted <==

Requirements) Regulations,2015and Part Aof attached as per 'AnnexureA'.	Schedule IIIofthe aforesaid regulations,is
a)Nameofthe target entity, details in briefsuch as size, turnover etc.;	i) Nameofthe Target:Tarsius Pharma Ltd. ("Tarsius") (Target)ii) Detailsofthe Target:Tarsius is an Israel based early stage researchanddevelopment companyfocusingondevelopmentofdrug candidates in the fieldofOphthalmology2017Sales: NIL
b) Whether the acquisition would fall withinrelated party transaction(s) and whether thepromoter/ promoter group/ group companieshave any interest in the entity being acquired?Ifyes, natureofinterest and details thereof andwhether the same is done at "arms-length";	No, the acquisition would not fall within therelated party transaction.
c) Industry to which the entity being acquiredbelongs;	Pharmaceuticals, Research and Development.
d)Objects and effectsofacquisition (including Investment in Target entity byanindirectbut not limited to, disclosureofreasons for whollyownedsubsidiaryofSunacquisitionoftarget entity, if its business is Pharmaceutical Industries Limited.outside the main lineofbusinessofthe listedentity);
e) Brief detailsofany governmental or No governmental or regulatory approvals areregulatoryapprovalsrequiredforthe required.acquisition;
f)Indicative time period for completionofthe Before15mSeptember2018acquisition;
g) Natureofconsideration - whether cash Cash consideration towards subscriptionofconsideration or share swap and detailsofthe sharesofthe Target entity.same;
h)Costofacquisition or the priceatwhich the Costofacquisition is US$ 3 million.shares are acquired;-=eutic~h
Registered Office: SPARC, Tandalja,Vadodara.,390p~~u~at,INDIA.~~U'.J.!~

i) Percentageofshareholding_I_control acquiredand_I_or numberofshares acquired;	345,622 ordinary shares representing 18.75%ofsharesofthe Target entity, on a fully dilutedbasis.
j)Brief background about the entity acquiredin termsofproducts/lineofbusiness acquired,dateofincorporation, historyoflast 3 yearsturnover, country in which the acquired entityhas presence andany other significantinformation (in brief);	Brief background:Tarsius is an Israel based early stage researchanddevelopmentcompanyfocusingondevelopmentofdrug candidates in the fieldofOphthalmology.**Dateofincorporation:**21 51February 2016**Turnoveroflast 3 years:**NIL**Lineofbusiness:**Early stage research anddevelopmentofdrug candidates in the fieldofOphthalmology.Country in which the Target entity haspresence:Israel

==> picture [90 x 78] intentionally omitted <==